Clovis Oncology, Inc. (CLVS)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.39+0.24 (+1.04%)
At close: 4:00 PM EDT
People also watch:
PBYIAGIOTSROCLDXICPT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open23.27
Prev Close23.15
Bid23.10 x 200
Ask23.99 x 500
Day's Range22.86 - 23.91
52wk Range11.57 - 116.75
1y Target EstN/A
Market Cap900.54M
P/E Ratio (ttm)-2.07
Beta1.72
Volume1,161,548
Avg Vol (3m)1,546,457
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals5 days ago

    Clovis boosted by FDA acceptance of cancer drug

    Shares of biotech firm Clovis Oncology Inc. were buoyed Tuesday by the U.S. Food and Drug Administration accepting a fast-tracked new drug application for the company's latest cancer drug. The Boulder-based company's (CLVS) stock rose 27 percent after it announced the application acceptance for the drug rucaparib, used to treat advanced ovarian cancer in women with a certain genetic profile. Being accepted means an accelerated FDA review of the drug's application and clinical trial data is scheduled to be finished by Feb. 23, 2017.

  • 5 Companies That Should Consider Kicking Their CEOs to the Curb
    Motley Fool5 days ago

    5 Companies That Should Consider Kicking Their CEOs to the Curb

    According to our Foolish contributors, these leaders are standing in the way of progress.

  • Our Take On The Clovis Oncology Inc (CLVS) Announcement
    Insider Monkey6 days ago

    Our Take On The Clovis Oncology Inc (CLVS) Announcement

    Clovis Oncology Inc (NASDAQ:CLVS) just reported that the FDA has accepted its new drug application (NDA) and the company is up close to 30% ahead of the market open in the US on Wednesday. This is a pretty big response to a relatively minor development. Don’t get us wrong, an acceptance is a positive step, […]